Interview: Jon Neal – Managing Director, Takeda UK and Ireland
As all eyes are on Takeda these days after its announced acquisition of Shire, Jon Neal, managing director of the UK and Ireland operations of the Japanese player, looks back…
Address: 61 Aldwych, London, WC2B 4AE, UK,United Kingdom
Tel: +44-20-3116-8000
Takeda is a research-based global pharmaceutical company. It is the largest pharmaceutical company in Japan, and one of the global leaders of the industry. Using their management philosophy, “Takeda-ism,” as the basis of business, Takeda is committed to striving towards better health for patients worldwide through leading innovation in medicine. Takeda is enhancing its R&D pipeline by concentrating its management resources.
Takeda’s in-house ethical drugs are marketed in around 90 countries worldwide. It has Research, Development, and Operations & Marketing Centers in the UK.
Ethical drugs are Takeda’s core business. Takeda provides ethical drugs across a range of therapeutic areas to meet the needs and expectations of medical professionals and patients around the world.
Their portfolio includes lansoprazole for the treatment of peptic ulcers, leuprolide acetate for the treatment of prostate cancer and endometriosis, pioglitazone hydrocholoride for the treatment of diabetes, and candesartan cilexetil for the treatment of hypertension.
These four drugs are designated as ‘international strategic products’ and Takeda is focusing on managing their product lifecycles to strengthen sales on a global level.
In addition, Takeda promotes enhancing its R&D pipeline, while concentrating its management resources to the four core therapeutic areas: lifestyle-related diseases, oncology and urological diseases, central nervous system disease and gastroenterological diseases.
As all eyes are on Takeda these days after its announced acquisition of Shire, Jon Neal, managing director of the UK and Ireland operations of the Japanese player, looks back…
Natalia Zago, managing director of Takeda Ukraine, one of the leading international companies operating in the country, provides insights into her main priorities to drive the growth of the company…
What is the importance of the UK operations for Takeda worldwide? Our UK operation was established in 1997 and is relatively younger than other affiliates in Europe such as Takeda…
Although biotech financing in the UK took a hit last year in large part thanks to uncertainty around Brexit, 2019 was still the British industry’s third-best year on record. …
GW Pharmaceuticals reports that sales of its CBD drug Epidiolex more than doubled in the second quarter of 2019, demonstrating that cannabinoid-based medicines can be highly profitable and potentially blazing…
Formed in 2015, listed UK start-up Amryt targets rare diseases with high unmet medical need. With one commercial asset on the market, a strong pipeline of development assets and a…
Hopes have been raised of a cure for AIDS after a patient in London became free of the HIV virus following a bone marrow transplant. Although it is not…
Founded in 1998, GW Pharmaceuticals is a British biopharmaceutical company, best known for being the only company with a license to cultivate cannabis in the UK. True pioneers, they are…
The 9th February 2019 marked the launch of the European Medicines Verification System (EMVS) which will use cutting-edge technology to safeguard the medicine supply chain against fake products. Each European country…
In recent years, apocalyptic conversations around superbugs caused by antimicrobial resistance (AMR) have been on the up, but just in case we were becoming immune to these warnings, the UK has…
An unusual characteristic of the UK’s healthcare landscape is that charities fund the vast majority of medical research. According to the Association of Medical Research Charities (AMRC), in 2017, 8 million people…
The two Big Pharma giants today announced the merger between their consumer healthcare businesses, with the joint venture (JV) set to become the global market leader in over-the-counter (OTC) products…
Ian Chamberlain looks at the changing role of the pharma sales manager and the skills needed to keep up with new tech and the next generation of millennial sales reps. With…
Aditya Bhattacharji manages Eurasia Group‘s healthcare analysis. In his second piece for PharmaBoardroom, Aditya examines the dangers of nationalism and populism for the private sector. The biggest global risk I see…
With more than 25 years pharmaceutical industry experience, Ian Chamberlain provides training to help pharma salespeople talk to customers and provides sales managers with software to help pharma companies intelligently listen…
See our Cookie Privacy Policy Here
